Biosimilarity Assessment of the Biosimilar Teriparatide Candidate and the Reference Drug in Healthy Subjects

• Published in: Clinical pharmacology in drug development Vol. 12; no. 5; pp. 518 - 524
• Main Authors: Wang, Xuan, Liang, Xintong, Wang, Tenghua, Zhan, Yaoxuan, Liu, Haiyan, Li, Chen, Li, Xianbo, Ma, Hui, Hu, Zhiqin, Wang, Xiaole, Xiao, Shuangshuang, Ban, Li, He, Jin, Li, Yongmei, Fang, Yi
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2023
• Subjects: Biological products; Biosimilar Pharmaceuticals; biosimilarity; Calcium; Healthy Volunteers; Humans; parathyroid hormone; pharmacokinetics; safety; SAL001; teriparatide; Teriparatide - adverse effects; Teriparatide - pharmacokinetics; Therapeutic Equivalency; pharmacokinetics; parathyroid hormone; SAL001; teriparatide; safety; biosimilarity
• ISSN: 2160-763X; 2160-7648
• DOI: 10.1002/cpdd.1221

SAL001, a recombinant form of parathyroid hormone, is a biosimilar drug to teriparatide and is planned to be used in osteoporosis treatment. A single‐dose, randomized, open‐label, 2‐way crossover trial was conducted in healthy subjects to compare the pharmacokinetics (PK) and safety between SAL001 and the reference drug. Sixty‐four subjects were enrolled in the study, and 61 subjects completed the study. In each period, 20 μg of the test or reference formulation was administered subcutaneously. SAL001 was administered by autoinjector pen, whereas the reference drug was administered by a self‐matched injection pen. Serial blood samples were obtained for the analyses of PK and serum calcium concentration. Geometric mean ratios with 90%CIs for the maximum plasma concentration (Cmax) and area under the plasma concentration–time curve (AUC) were estimated. The safety of these 2 formulations was also evaluated. Overall, the 90%CIs for the geometric mean ratios of Cmax, AUC from time 0 to the last quantifiable time point, and AUC from time 0 extrapolated to infinity of the test or reference product were within 80.0%–125.0% of biosimilarity criteria. Other PK parameters, serum calcium concentration, and safety profiles had no significant differences between the 2 formulations. SAL001 demonstrated PK similarity to the reference drug, and the serum calcium concentration and safety profiles of SAL001 were also considered comparable to the reference drug.